Literature DB >> 1083267

[Anti-immunoglobulins in multiple myeloma and benign monoclonal hyperglobulinemia].

I Schedel, P C Fink, J Kalden.   

Abstract

Sera from 50 healthy adults, from 21 patients with multiple myeloma (MM) and from 11 patients with benign monoclonal hyperglobulinaemia (BMH) and from 28 patients with sarcoidosis were examined for the presence of anti-IgG-activity by passive haemagglutination technique. 62% of healthy adults (titre less than 2) and all of the sera from patients with MM and BMH (titres 32-512) as well as 42% of the sera from sarcoidosis patients were found to be anti-IgG positive. The anti-IgG positive sera showed also anti-(Fab)2-activity (with the exeption of 2 sera from sarcoidosis patients). No significant differences could be found between anti-Ig activity in sera from MM patients with BMH. There was also seen no correlation of anti-Ig with the clinical course of the disease. After column chromatography we could detect the partially simultaneous presence of anti-Ig with anti-Fc-specificity (MW ca. 900,000) and with (Fab)2-specificity (MW 150,000 or less than 90,000). Antibody dependent cytotoxicity (using melanoma cell lines as targets) was significantly inhibited by the isolated anti-Ig-fractions with low molecular sizes (MW less than 90,000). From these results it seems possible that anti-immunoglobulins may play a role in the clinical course of the disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1083267     DOI: 10.1007/bf01005309

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  3 in total

1.  Presence and possible role of anti-IgG antibodies in human malignancy.

Authors:  D Hartmann; M G Lewis
Journal:  Lancet       Date:  1974-06-29       Impact factor: 79.321

2.  Anit-immunoglobulins in multiple myeloma.

Authors:  N I Abdou; N L Abdou
Journal:  Clin Exp Immunol       Date:  1972-05       Impact factor: 4.330

3.  Serum anti-immunoglobulins in multiple myeloma and benign monoclonal gammopathy.

Authors:  R C williams
Journal:  Clin Immunol Immunopathol       Date:  1975-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.